Latest News - Moderna
Top Corporates Hub
Moderna
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
25.07.2026 00:30
The days ahead pack several binary or near-binary catalysts for U.S. biotech and biopharma companies—decisions that could sharply reshape valuations overnight.
Dassault Systemes SE (DASTF) (H1 2026) Earnings Call Highlights: Strong Subscription Growth and ...
23.07.2026 15:01
Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
23.07.2026 15:00
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
22.07.2026 10:00
CHICAGO, July 22, 2026--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in "Hallucinating Value: Healthcare's AI Narrative."
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?
22.07.2026 04:29
Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit Committee, as the stock recently declined 3.77% and an earnings report is scheduled for July 31, 2026. See our latest analysis for Moderna. Moderna shares have been volatile, with the 7-day share price return down 11.54% and the 30-day share price return down 6.72%. However, the year to date share price return of 93.32% and 1-year total shareholder return of 82.28%...
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift
22.07.2026 03:20
Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee. The company has adjusted certain Board committee memberships alongside his appointment. The changes bring additional financial and life sciences experience into Moderna’s governance structure. Moderna, traded on NasdaqGS:MRNA, is drawing attention for a fresh governance update rather than product news. The stock closed at $59.66, with returns up 93.3% year to date and up 82.3% over the past year, set...
Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $67
21.07.2026 08:41
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $49 to $67.
Neglected Quant Safety Trade Makes a Comeback as AI Risks Rise
17.07.2026 11:44
(Bloomberg) -- As worries build around the artificial intelligence trade, investors are starting to seek shelter in a more pedestrian corner of the stock market: companies with sturdy finances.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthNasdaq Futures Tumble 1.5% as Chip Rout Deepens: Markets WrapUS Cyclospora Outbreak Tied to
Moderna, Takeda and Capricor on the verge of notching big drug approvals
13.07.2026 08:20
Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.
Moderna secures up to 24 million RSV vaccine dose contract with Europe
09.07.2026 17:11
Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
09.07.2026 11:00
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide ...
RBC Capital Raises its Price Target on Moderna (MRNA)
09.07.2026 10:41
Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said […]
Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative?
09.07.2026 10:12
On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...
Moderna Appoints Michael McDonnell to Board of Directors
08.07.2026 11:00
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell ...
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
07.07.2026 18:28
Arbutus expects to receive around $179 million from Moderna.
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says
07.07.2026 15:04
Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny
RBC Capital Maintains Sector Perform on Moderna, Raises Price Target to $45
07.07.2026 12:01
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and raises the price target from $38 to $45.
B of A Securities Maintains Underperform on Moderna, Raises Price Target to $38
07.07.2026 10:23
B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $34 to $38.
ValuEngine Weekly Market Summary And Commentary
07.07.2026 07:05
US equity markets were mixed over last week, with broad index performance modestly positive but sector leadership uneven. The S&P 500 ETF gained 0.56% but the NASDAQ 100 ETF declined 1.55%.
Is Moderna Stock a No-Brainer Buy After a Key FDA Win?
30.06.2026 18:35
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.